...
首页> 外文期刊>BMC Cancer >Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis
【24h】

Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis

机译:18F-FDG PET-CT的长期结果和复发模式在转移结直肠癌的一线治疗中的第一线治疗中的代谢反应:基于病变和基于患者的分析

获取原文
           

摘要

18F-FDG PET-CT is commonly used to monitor treatment response in patients with metastatic colorectal cancer (mCRC). With improvement in systemic therapy, complete metabolic response (CMR) is increasingly encountered but its clinical significance is undefined. The study examined the long-term outcomes and recurrence patterns in these patients. Consecutive patients with mCRC who achieved CMR on PET-CT during first-line systemic therapy were retrospectively analysed. Measurable and non-measurable lesions identified on baseline PET-CT were compared with Response Criteria in Solid Tumors (RECIST) on CT on a per-lesion basis. Progression free (PFS) and Overall Survival (OS) were compared with clinical parameters and treatment characteristics on a per-patient basis. Between 2008 and 2011, 40 patients with 192 serial PET-CT scans were eligible for analysis involving 44 measurable and 38 non-measurable lesions in 59 metastatic sites. On a per-lesion basis, 46% also achieved Complete Response (CR) on RECIST criteria and sustained CMR was more frequent in these lesions (OR 1.727, p?=?0.0031). Progressive metabolic disease (PMD) was seen in 12% of lesions, with liver metastasis the most common. Receiver operating characteristics (ROC) curve analysis revealed the optimal value of SUVmax for predicting PMD of a lesion was 4.4 (AUC 0.734, p?=?0.004). On a per-patient basis, 14 patients achieved sustained CMR and their outcomes were better than those with PMD (median OS not reached vs 37.7?months p?=?0.0001). No statistical difference was seen in OS between patients who achieved PR or CR (median OS 51.4 vs 44.2?months p?=?0.766). Our results provided additional information of long-term outcomes and recurrence patterns of patients with mCRC after achieving CMR. They had improved survival and sustained CMR using systemic therapy alone is possible. Discordance between morphological and metabolic response was consistent with reported literature but in the presence of CMR the two groups had comparable outcomes.
机译:18F-FDG PET-CT通常用于监测转移结直肠癌患者的治疗响应(MCRC)。随着全身治疗的改善,越来越多地遇到完全代谢反应(CMR),但临床意义是未定义的。该研究检测了这些患者的长期结果和复发模式。回顾性分析了在一线全身疗法期间达到PET-CT上的MCRC的MCRC患者。将在基线PET-CT上鉴定的可测量和不可测量的病变与在每个病变的CT上的固体肿瘤(再次recist)的响应标准进行比较。将进展免费(PFS)和整体存活(OS)与临床参数和治疗特征进行比较。 2008年至2011年间,40例192名串行PET-CT扫描患者有资格进行分析,涉及44种可测量的44种可测量和38个非可测量病变。在每个病变的基础上,46%也实现了重新准则的完整反应(Cr),并且在这些病变中持续的CMR更频繁(或1.727,p?= 0.0031)。在12%的病变中观察到进行性代谢疾病(PMD),肝脏转移最常见。接收器操作特性(ROC)曲线分析显示了Suvmax用于预测病变的PMD的最佳值为4.4(AUC 0.734,P?= 0.004)。在每位患者的基础上,14名患者实现了CMR,其结果优于PMD的结果(中位OS没有达到37.7?月P?= 0.0001)。在达到PR或CR的患者之间没有观察到统计差异(中位数OS 51.4 VS 44.2?月份P?= 0.766)。我们的结果提供了在实现CMR后患有MCRC患者的长期结果和复发模式的更多信息。它们可以通过单独使用全身疗法提高存活率和持续的CMR。形态学和代谢反应之间的不间断与报告的文献一致,但在CMR存在下,两组具有可比的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号